IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced significant enhancements to its global suite of patient-centered longitudinal disease and treatment insights. Drawing from information on more than 250 million anonymized patients, the IMS LifeLink(TM) portfolio of information, analytics and consulting offerings delivers expanded, more relevant metrics for understanding healthcare market dynamics and shaping effective commercial strategies. IMS LifeLink enables pharmaceutical and biotech companies, medical researchers, government agencies, payers and other stakeholders to define appropriate clinical requirements, understand treatment patterns, and gauge disease progression for improving healthcare outcomes.
“The pharmaceutical landscape has changed dramatically in recent years, and a patient-centered perspective is essential to understanding the market environment,” said David Carlucci, chairman and CEO, IMS. “Our anonymized patient-level insights set the standard for demonstrating the value of medicines and optimizing commercial effectiveness – both at a portfolio and product level. Only IMS has made the extensive global investments needed to bring together a full range of capabilities to help healthcare stakeholders assess and respond to patient needs.”
IMS LifeLink enhancements seamlessly integrate the company’s comprehensive longitudinal prescription information and sub-national anonymized patient-level metrics with its provider-level prescription databases. With more granular information, clients can make informed decisions earlier in the product lifecycle, and realize meaningful performance and productivity gains. In addition, they can define patient populations that will derive the greatest clinical benefits from the right products, and engage prescribers with more timely, relevant information about treatments and therapies.
Recent IMS LifeLink offerings enhancements include:
— IMS Xponent Prescribing Dynamics(TM)- Expanded prescriber-level coverage in the U.S. extends anonymized patient-level analytics. As a result, clients can more precisely define patient segments that would benefit from their products, and better educate physicians about treatment variability.
— IMS NPA Market Dynamics(TM) – New views by diagnosis, ethnicity and treatment adherence enable clients to more effectively measure therapy use by patient type, as well as monitor overall compliance in the drive to improve patient outcomes.
— IMS Disease Dynamics On-Line(TM) – A recently launched Web-enabled tool in the U.K. supports fast access to information and guided analyses. Clients can more readily understand the true market potential of new medications and define patient populations based on current treatment patterns.
— IMS New-to-Brand – A new patient-based offering in Canada provides greater visibility into the volume of anonymized first-time prescriptions for retail brands treating chronic diseases.
— Consulting Studies – A broad range of custom studies leverages IMS’s disease and treatment information for insights across all major therapeutic areas and multiple geographies. By bringing together the company’s extensive information, analytics and consulting capabilities, IMS addresses critical client issues related to commercial effectiveness, product and portfolio strategy, and the value of medicines.
“Our team of experts applies real-world information to both anticipate and address evolving market and treatment dynamics,” said Ray Hill, general manager, Consulting and Services, IMS. “With IMS LifeLink, anonymized patient-level insights are at the forefront of clinical and commercial decisions – strengthening the link between specific diseases and available therapies. We’re uniquely qualified to help move the industry to a more unified approach to improving treatment of patients, measuring quality of care and managing costs.”
About IMS
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.2 billion in 2007 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.
As a global leader in protecting individual patient privacy, IMS uses de-identified healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.
Comments